Arrowhead Pharmaceuticals appoints Dr. Matt Cohen to its board of directors

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) announced that its Board of Directors appointed Dr. Matt Cohen, M.D., M.B.A., as a director of the company, effective June 12, 2026.

Dr. Cohen currently serves as Managing Director at Vida Ventures, a position he has held since 2025. Prior to that, he spent two decades at JP Morgan Asset Management, where he served as a portfolio manager and lead growth-focused healthcare investor starting in 2005. His roles there included lead portfolio manager of the JP Morgan Global Healthcare Fund and co-portfolio manager of the JP Morgan Small Cap Growth Fund.

Before joining JP Morgan Asset Management, Dr. Cohen was a senior analyst at Medici Healthcare from 2003 to 2005 and at Narragansett Asset Management from 2000 to 2003, both New York-based healthcare hedge funds. Earlier in his career, he worked as a categorical resident surgeon in the Department of General Surgery at North Shore University Hospital – NYU School of Medicine.

Dr. Cohen holds an M.B.A. from New York University's Stern School of Business and an M.D. from McGill University in Montreal.

You May Also Be Interested In

• Getty Images strikes multi-year display deal with OpenAI for ChatGPT
• Corporación América Airports posts flat May traffic as domestic declines
• Teva submits NDA for ecopipam to treat pediatric Tourette syndrome